There have been reports of strong correlations between poor prognosis in various cancers and concomitant expression of urokinase-type plasminogen activator (uPA) and its surface receptor (uPAR). We and others have previously shown that the uPA system plays a significant role in a subset of head and neck squamous cell carcinoma. In the present study, we found that uPAR is required for invasion and 
Introduction
Several proteolytic enzyme systems, involving plasminogen activators (PAs), matrix metalloproteinases (MMPs) and other enzymes, are thought to be intimately involved in invasion and metastasis of tumor cells [1] . Urokinase-type PA (uPA), which plays an essential role in conversion of PA to active plasmin and proteolysis of extracellular matrix (ECM), has been implicated in cancer cell invasion and metastasis [2, 3] . In particular, the activity of receptor (uPAR)-bound uPA is an important factor in the degradation ECM [4, 5] .
In a previous study, we found that cells overexpressing both uPAR and uPA mRNA were more invasive and aggressive in an in vivo experimental metastasis model [6] . In immunohistochemical studies, the uPA system has been found to be significantly associated with mode of invasion [7] and secondary regional lymph node metastasis of squamous cell carcinoma (SCC) in the oral cavity [8] . The majority of studies of the uPA system in oral SCC have shown that patterns of expression of the uPA system correlate with metastatic ability of cancer cells or clinicopathological observations. In the present study, we examined overexpression of uPAR mRNA in OSC-19 cells derived from human oral SCC, and examined the function of uPAR using antisense oligodeoxynucleotides (AS-ODNs) and small interfering RNA (siRNA). We found that uPAR is required for invasion and metastasis of OSC-19 cells in the present in vivo models. Additionally, transfection of cells with uPAR siRNA inhibited degradation of fibronectin. These findings provide the first direct, conclusive evidence that reduction of uPAR expression by antisense nucleic acid can effectively inhibit progression of oral SCC.
Materials and Methods
Cell line and antibodies 
ODNs
An 18-mer ODN phosphodiester was used to inhibit uPAR gene expression [9] . The ODNs were protected against exonuclease cleavage by a double substitution at the 3'-end and 5'-end with phosphorothioate residues, and were purified by high-performance liquid chromatography (JBioS, Asagiri, JAPAN). The AS-uPAR corresponded to nucleotides 44 to 61 of the human uPAR gene cDNA sequence [10] .
The controls consisted of sense (S)-and nonsense (NS)-ODNs (same base composition as AS-uPAR, but in random order) for uPAR. The sequence of the NS-uPAR was 5'-CCTGGGTCAGCGCGCTAG-3'. Cells were suspended in EMEM at a density of 10 6 cells/ml, and were incubated with medium alone or with 40 µM ODNs for 60 min at 37°C. Cell viability exceeding 95% was confirmed by trypan blue exclusion before ODN-treated cells were used in experiments.
Reverse transcription (RT)-PCR
RT-PCR analysis was performed using the modifications of Conboy et al. [11] .
Briefly, total RNA was extracted from cancer cells using a guanidinium-isothiocyanate-phenol-chloroform-based method (ISOGENE, Nippon Gene, Tokyo, Japan). The prepared RNA was mixed with the oligo-dT primer, incubated for 15 min at 68°C, and then quickly chilled on ice for 5 min. The RNA samples were reverse-transcribed into first-strand cDNA at 42°C for 60 min in RT solution [11] . The cDNA samples were amplified by adding a PCR mixture [11] . The amplification was performed as described previously by Noguchi-Takino et al. [12] . Primers for the uPAR and ß-actin genes were used as described by Noguchi-Takino et al. [12] . The lengths for the amplified fragments of the uPAR and ß-actin genes were 455 and 592 bp, respectively.
For quantitation, PCR product values of the uPAR gene, falling within the linearity range, were normalized to that of the ß-actin gene, which was used as an internal standard.
Orthotopic implantation model
The mode of cancer invasion in a tumor-host relationship closely correlates with clinical course. In a study of SCC of the oral cavity, Yamamoto et al. [7] graded mode of invasion, and showed that grade 4C and 4D (diffuse invasion) had poor prognosis. To evaluate the effect of AS-uPAR on mode of invasion, we injected cells pretreated with ODNs into the submucosa of the oral floor. The present xenograft model is described in detail elsewhere by Kawashiri et al. [13] . Briefly, 6-week-old female BALB/c nude mice (Charles River Japan, Yokohama, Japan) were used. Tumor cells (2 x 10 5 cells/mouse) were injected into the submucosa of the oral floor using a microsyringe with a 27-gauge needle. After 7 days, the tumors were excised and examined histopathologically.
In this orthotopic implantation model, the OSC-19 cells deeply invade, forming small cordlike cancer nests, which indicate grade 4C mode of invasion [13] .
Chick embryo assay
The metastatic ability of OSC-19 cell lines pretreated with ODNs was examined using the chick embryo assay. The assay for metastasized cells was performed as described previously by Endo et al. [14] . Briefly, fertilized chicken eggs were incubated in a forced-air incubator at 37˚C in a humidified atmosphere. Tumor cells In each experiment, a series of cells was used for RT-PCR to evaluate inhibition of uPAR expression.
In vitro fibronectin degradation/invasion assays
We investigated the possibility that uPAR is involved in invasiveness of OSC-19 cells, using the fibronectin degradation/invasion assay with OSC-19 cells transfected with siRNA targeting uPAR. Cells transfected with the oligoribonucleotides were collected by trypsinization, and 10 5 cells were added to FITC-fibronectin-coated crosslinked gelatin films on an 18-mm round glass cover slip in a 12-well plate, as described elsewhere [15, 16] . This technique allows us to measure the fibronectin degradation and the invasiveness in terms of foci of invadopodial extensions and surface indentations in the crosslinked gelatin film. Invasive cells locally degrade the FITC-fibronectin-coated matrix, leaving a dark area easily detectable by immunofluorescence microscopy in the in vitro fibronectin degradation/invasion assay, as described in detail elsewhere [15, 16] . After the cells were allowed to grow on the films for the indicated periods of time, they were examined using an MRC-1024 confocal laser-scanning microscope (Bio-Rad, UK). To quantify the degraded area of FITC-fibronectin, we used NIHimage to calculate the area of the black region (30 pixel <) and the black dots (30 pixel >), which indicated fibronectin degradation.
Statistics
All experiments were repeated 3 times, and similar results were obtained each time. The statistical significance of differences between groups was evaluated using a single sample two-tailed Student's t test.
Results

Effect of treatment with AS-uPAR on uPAR mRNA level
The pretreatment of OSC-19 cells for 60 min with 40 µM AS-uPAR resulted in a dramatic decrease of uPAR mRNA levels ( Figure 1 ). The cells treated with S-or NS-uPAR had the same uPAR/ß-actin ratio as the control cells. The cells treated with AS-uPAR had a uPAR/ß-actin ratio that was 57% less than that of the control cells.
Effects of ODNs for uPAR on mode of invasion
In control groups that were untreated or were pretreated with S-or NS-uPAR, all oral floor tumors were Grade 4C. In contrast, in the group pretreated with AS-uPAR, diffuse invasion was inhibited and the tumors were Grade 3; i.e., they consisted of groups of cells without a distinct borderline (Figure 2 ). In the group treated with AS-uPAR intratumorally on day 3 after the injection of untreated tumor cells, the tumors were the same as in the control groups.
Effects of pretreatment with ODNs for uPAR on experimental metastases
In control groups, metastasized cells were observed in the chick liver ( Figure   3 ) ( Figure 6B ).
Discussion
In the present study, we showed that AS-uPAR inhibits overexpression of uPAR in highly malignant oral cancer cells . We also demonstrated that uPAR plays an important role in the progression of oral cancer cells. We observed an especially strong relationship between the uPA system and initial invasion of oral cancer cells.
A specific cell surface receptor for the ligand uPA catalyzes the formation of plasmin from PA, thus generating the proteolytic cascade that contributes to the breakdown of ECM, which is a key step in cancer metastasis [2, 3] . Recent studies by
Aguirre-Ghiso et al. have demonstrated signaling via uPAR in cancer cells in vivo [17, 18] . They showed that a large reduction in the uPAR level induced a protracted state of tumor dormancy, but did not affect in vitro growth [17] . Further analysis revealed that the overexpressed uPA/uPAR complex interacted strongly with α5ß1 integrin, resulting in powerful and persistent activation of the Mek-ERK pathway upon binding to fibronectin [17, 18] . When uPAR was downregulated or the uPAR-α5ß1 interaction was disrupted, the ERK pathway became deactivated, the cell arrested in the G0/G1 phase of the cell cycle in vivo, and tumor dormancy was triggered in vivo [17, 18] . In the present study, AS-uPAR inhibited invasion and metastasis in vivo but did not inhibit in vitro growth. This suggests that the same mechanism is at work in the present in vivo experimental models and the studies by Aguirre-Ghiso et al. α5ß1 integrin is the fibronectin receptor, and the uPAR siRNA decreased the fibronectin degradation.
Recent reports suggest that regulation of uPAR expression is a viable method of controlling cancer progression in vivo. Crowley et al. [19] reported that a mutant uPA molecule that binds to uPAR but lacks enzyme activity inhibited metastasis of PC3 prostate cancer cells in an immunodeficient mouse model. Similarly, blocking uPAR with the epidermal growth factor-like domain of murine uPA suppresses neovascularization and growth of B16 melanomas [20] . Recently, researchers have developed various agents that target uPAR, including AS-ODN, siRNA, protein and peptide-based drugs [21] [22] [23] . These reports suggest that uPAR is a promising therapeutic target for regulation of cancer progression. The present results indicate that our strategy for targeting uPAR is an effective method of inhibiting progression of oral SCC.
However, in previous in vivo studies, cancer progression was only weakly inhibited by antisense uPAR mRNA. This discrepancy may be due to the activity of other proteinases (including MMPs) that play central roles in the process of cancer invasion and metastasis. OSC-19 cells express high levels of some MMPs (data not shown).
Therefore, in addition to reduction of uPAR expression, other strategies may be needed to obtain more effective and reliable inhibition of cancer progression.
The uPAR promoter region is located in a 188-bp region between bases -141 and +47, relative to the transcription start site [3] . Binding of transcription factors (Sp1, AP-2, NF-κB and 2 molecules of AP-1) to the uPAR promoter region activates basal transcription of the gene. NF-κB also induces expression of proteinases (uPA, MMP-1, and -9) [24] [25] [26] . Thus, drugs that inhibit activity of NF-κB may inhibit cancer invasion and metastasis. We have previously shown that parthenolide, an active ingredient of herbal remedies such as feverfew (tanacetum parthenium), decreases NF-κB DNA-binding activity and expression of target genes of NF-κB [27, 28] . In studies of the uPAR promoter, Shiratsuchi et al. [29] and Hapke et al. [30] cells/egg) pretreated with ODNs were injected into the CAM vein of 10-day-old chick embryos. After 7 days, 6 embryos from each group were sacrificed and the liver DNA was extracted. The sample DNA was analyzed by PCR using a primer pair specific to the human ß-globin gene. 
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